Intimation for Re-Constitution of Audit Committee, Nomination and Remuneration Committee and Stake Holders and Relationship Committee
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs reported audited FY25 revenue of ₹11,335 lakhs, down about 28% from ₹15,671 lakhs in FY24, with net profit falling to ₹438 lakhs (vs ₹555 lakhs). Q4 FY25 revenue stood at ₹2,550 lakhs and net profit at ₹89 lakhs. EPS for FY25 was ₹5.82 (vs ₹7.37). The statutory auditor (M/s Ayyadevara & Co.) issued an unqualified opinion, and the company has no defaults on loans or debt. Two Independent Directors — Mr. Syed Anis Hussain and Mrs. Vimala Behram Madon — will retire on June 23, 2025 after completing two consecutive 5-year terms. Mrs. Shilpa Bung (CS and LLB background) has been appointed as a new Independent Director for 5 years. The Audit, Nomination & Remuneration, and Stakeholders Relationship Committees have been reconstituted effective June 23, 2025.
Shareholders should note the clear decline in both revenue and profitability for FY25, which is the more significant story here. The board churn is routine (term-based retirement of two long-serving independent directors and appointment of a replacement), so no governance alarm is raised. The 37th AGM is scheduled for August 28, 2025.